SRR8392882
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.570
- IL6_JAK_STAT3_SIGNALING+0.490
- INFLAMMATORY_RESPONSE+0.430
- ALLOGRAFT_REJECTION+0.400
- COMPLEMENT+0.360
- ANGIOGENESIS+0.350
- GLYCOLYSIS+0.340
- APOPTOSIS+0.310
- PROTEIN_SECRETION+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.260
- MYC_TARGETS_V1-0.230
- MYC_TARGETS_V2-0.230
- WNT_BETA_CATENIN_SIGNALING-0.230
- DNA_REPAIR-0.160
- G2M_CHECKPOINT-0.150
- KRAS_SIGNALING_DN-0.150
- SPERMATOGENESIS-0.150
- APICAL_SURFACE-0.130
- CHOLESTEROL_HOMEOSTASIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02242 | — | cohortA1 | 0.880 |
| 2 | BS_W3R88RFP | pilocytic astrocytoma | — | 0.866 |
| 3 | SRR934908 | — | — | 0.856 |
| 4 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.843 |
| 5 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.840 |
| 6 | s0112287 | — | — | 0.832 |
| 7 | SRR8518406 | — | D | 0.832 |
| 8 | SRR8518287 | — | C | 0.830 |
| 9 | TCGA-69-7974-01A-11R-2187-07 | — | cohortA1 | 0.829 |
| 10 | SRR934901 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |